Phase 2 N=35 Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
Cushing's Syndrome
Primary: Percentage of Participants With One or More Adverse Events — 15; 18 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=137 Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
Cushings Disease
Primary: Percentage of Primary Efficacy Responder at Week 34 by Randomized Treatment and Strata — 86.1; 29.4 Percentage of participants — p=<.001
Phase 2 N=19 Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease
Cushing Disease
Primary: Percentage of Responders With Mean Urinary Free Cortisol (UFC) Within Normal Limits — 22.2 percentage of responders
N/A N=152 Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease
Cushings Disease
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability Profile of Pasireotide s.c. — 11; 13; 34; 54 Participants
Phase 4 N=249 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly
Cushing's Disease · Acromegaly
Primary: Change in HbA1c From Randomization to Approximately 16 Weeks — -0.12; 0.26; 0.33; 0.45 Hba1c percentage
Phase 2 N=9 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome
Cushing's Syndrome · Ectopic Corticotropin Syndrome · Adrenal Adenoma
Primary: Percent Change in the Mean Urine Free Cortisol (mUFC) at the Individual Level at Week 12 — -99.0; -97.8; -94.5; -91.5 percentage change
Phase 2 N=68 New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome
Cushing Syndrome · Endocrine Disease
Primary: Sensitivity of Imaging Modalities for the Detection of ACTH-secreting Non-pituitary Tumor in Patients — 96.3; 77.1; 66.7; 100 percentage of patients
Phase 3 N=73 Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease
Cushing's Disease
Primary: Percentage of Randomized Participants With a Complete Response — 37; 2 Participants — p=<.0001
Phase 3 N=150 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
Cushing's Disease
Primary: Percentage Participants That Attained a mUFC ≤ 1.0 x ULN at Month 7 Regardless of Dose Titration — 41.9; 40.8 percentage of participants
Phase 2 N=12 Safety and Efficacy of LCI699 in Cushing's Disease Patients
Cushings Disease · Cushing Disease
Primary: Percentage of Responders to LCI699 Based on the Change in Mean Urinary Free Cortisol (UFC) From Baseline to Week 10 — 100.0 Percentage of participants
Phase 3 N=104 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
Cushing's Disease
Primary: Percentage of Patients With a Drug-related Adverse Event That is Recorded as Grade 3 or 4 or as a Serious Adverse Event (SAE) — 53.1; 53.1; 29.1; 27.3 percentage of…
Phase 3 N=162 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
Cushing's Disease
Primary: Number of mUFC (Urinary Free Cortisol) Responders by Randomized Dose Group — 12; 21 Responders
N/A N=103 Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome
Cushing's Syndrome
Primary: Effectiveness of Osilodrostat — 23 Participants
Phase 3 N=30 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Cushing's Syndrome
Primary: Number of Participants With Adverse Events — 30 participants
Phase 3 N=79 A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.
Endogenous Cushing's Syndrome
Primary: Number of Subjects With Loss of Therapeutic Response to Levoketoconazole Upon Withdrawing to Placebo Compared With the Proportion of Subjects With Loss of Therapeutic…